세계의 방사선 피부염 시장 규모, 점유율, 동향, 예측 : 제품, 유통 채널, 지역별(2025-2033년)

The global radiodermatitis market size was valued at USD 514.78 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 668.02 Million by 2033, exhibiting a CAGR of 2.94% from 2025-2033. Asia Pacific currently dominates the market, holding a market share of over 34% in 2024. The radiodermatitis market share is expanding, driven by the increasing numbers of cancer patients worldwide, heightened advancements in treatment modalities, and rising demand for the non-invasive, patient-centered treatments.

Radiodermatitis, or radiation dermatitis, refers to a skin condition caused due to radiation therapy used for the treatment of cancer. It generally occurs as a side effect during cancer treatment or after interventional radiology in patients with cancers of the breast, lungs, skin, neck, head or perineum region where the skin is part of the target field. Some of the commonly used products to treat radiodermatitis include topical antibiotics, corticosteroids, hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, and anti-inflammatory agents. In recent years, radiodermatitis treatment has gained traction as it helps reduce discomfort, minimize pain and prevent interruption in ongoing therapy while improving the overall quality of the patient's life.

Radiodermatitis Market Trends:

The widespread prevalence of cancer and the rising adoption of radiation therapy as a treatment option represent the primary factors driving the market growth. Besides this, the increasing geriatric population across the globe and the growing need to counter the adverse side effects of radiation therapy are augmenting the demand for radiodermatitis treatment. Additionally, numerous governing and non-governing agencies are taking favorable initiatives to spread awareness regarding the available radiodermatitis treatment and management products. This, in confluence with the rising public and private investments in the ongoing research and development (R&D) activities in the field of life sciences, is catalyzing the market growth. Furthermore, the leading players are focusing on developing innovative product variants to expand their product portfolio and gain a competitive edge. Moreover, the rising number of clinical trials, favorable government policies, increasing consumer expenditure capacities, improving healthcare infrastructure and easy availability of generic drugs are some of the other factors creating a positive market outlook.

Key Market Segmentation:

Breakup by Product:

• Topical
• Corticosteroids
• Hydrophilic Creams
• Antibiotics
• Others
• Oral
• Dressings
• Hydrogel and Hydrocolloid Dressings
• No Sting Barrier Film
• Honey Impregnated Gauze
• Silicone Coated Dressings
• Others

Breakup by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Molnlycke Health Care AB and Stratpharma AG.

Key Questions Answered in This Report

• 1.How big is the radiodermatitis market?
• 2.What is the future outlook of radiodermatitis market?
• 3.What are the key factors driving the radiodermatitis market?
• 4.Which region accounts for the largest radiodermatitis market share?
• 5.Which are the leading companies in the global radiodermatitis market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Radiodermatitis Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Topical
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Corticosteroids
    • 6.1.2.2 Hydrophilic Creams
    • 6.1.2.3 Antibiotics
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 Oral
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Dressings
  • 6.3.1 Market Trends
  • 6.3.2 Key Segments
    • 6.3.2.1 Hydrogel and Hydrocolloid Dressings
    • 6.3.2.2 No Sting Barrier Film
    • 6.3.2.3 Honey Impregnated Gauze
    • 6.3.2.4 Silicone Coated Dressings
    • 6.3.2.5 Others
  • 6.3.3 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Retail Pharmacy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Pharmacy
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 3M Company
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Bausch Health Companies Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 Bayer AG
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 BMG PHARMA S.p.A.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
  • 13.3.5 Charles River Laboratories International Inc.
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 ConvaTec Group plc
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Helsinn Healthcare SA
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
  • 13.3.8 ICON plc
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Integra LifeSciences
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Molnlycke Health Care AB
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 SWOT Analysis
  • 13.3.11 Stratpharma AG
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio